Tango Therapeutics, Inc.

TNGXNASDAQ • USD
ThemeHealthcare - Oncology›Targeted Therapy & Precision Oncology
20.22 USD
↘ 1.93 (8.71%)AT CLOSE (11:59 AM EDT)
20.75
↗ 0.53 (2.62%)
POST MARKET (AS OF 06:50 PM EDT)
Post Market
AS OF 06:50 PM EDT
20.75
↗ 0.53 (2.62%)
🔴Market: CLOSED
Open?$22.02
High?$22.16
Low?$19.43
Prev. Close?$22.15
Volume?4.0M
Avg. Volume?3.0M
VWAP?$20.35
Rel. Volume?1.33x
Bid / Ask
Bid?$19.05 × 1.0K
Ask?$21.08 × 400
Spread?$2.03
Midpoint?$20.06
Valuation & Ratios
Market Cap?2.9B
Shares Out?144.6M
Float?129.0M
Float %?89.4%
P/E Ratio?N/A
P/B Ratio?7.47
EPS?-$0.74
Dividend?0.00%
Ex-Dividend?N/A

TNGX is currently priced at $20.22. Technicals currently rate "Sell" while our fundamental analysis reads "Neutral". This is driven by a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. On the valuation front, TNGX trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
Themes
Healthcare - Oncology›Targeted Therapy & Precision Oncology
Employees
137
Market Cap
2.9B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.tangotx.com
Listed
2021-08-11
Address
201 BROOKLINE AVENUE
BOSTON, MA 02215
Phone: (857) 320-4900
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
50
Short Sent.?
29
Piotroski F-Score?0/9Weak
Altman Z-Score?37.82Safe
Confidence?49%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?24.67%Squeeze Risk
Short Interest?31.8M
Days to Cover?10.0
Free Float129.0M
Avg Daily Volume3.2M
Settlement Date2026-05-15
Financial Health
Current Ratio?27.38Strong
Quick Ratio?27.38Strong
Cash Ratio?11.01Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
58/100
P/E?
N/A▾
P/B?
Peers
100
S&P
25
7.47FAIR▾
P/S?
Peers
100
S&P
3
51.32HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-24.0CHEAP▾
EV/Sales?
Peers
100
S&P
3
48.55HIGH▾
Returns & Efficiency
ROE?
S&P
6
-27.4%WEAK▾
ROA?
S&P
3
-24.6%WEAK▾
Cash Flow & Enterprise
FCF?$-142544000
Enterprise Value?$2.8B
Fundamentals ratios updated end of day
MarketsMoversWatchlist